Infirst Raises $38 Million From Invesco for Cold Medicine Market

Infirst Healthcare said it raised 25 million pounds ($38 million) from Invesco Asset Management to help break into the $20 billion market for cold and pain medicines.

Infirst plans to introduce its initial product, a cocoa- flavored cough liquid, in Europe, and is conducting late-stage trials on a non-narcotic, non-opioid cough treatment that may reach the market by 2015, the London-based company said in a statement today. Closely held Infirst also said it’s developing an ibuprofen-based product for inflammatory pain.

“Cough and cold and pain are the largest and most prevalent conditions in the consumer-health sector and represent an enormous opportunity for Infirst,” Chief Executive Officer Manfred Scheske said in the statement. “We are delighted that Invesco has become a major shareholder in our company.”

Scheske was president of GlaxoSmithKline Plc’s European consumer health-care business until 2010. Infirst Chief Financial Officer Andrew Waters also worked at London-based Glaxo.

Infirst is a spin-out from Seek, a London-based privately- owned drug discovery group. The company’s board includes former investment bankers Lynn Drummond, who was a managing director at Rothschild, and Kimbell Duncan.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.